About Fortrea
Spun out of Labcorp in 2023, Fortrea entered the contract research organisation market as an independent company with decades of accumulated trial execution expertise behind it. Headquartered in Durham, North Carolina, the organisation operates across more than 90 countries and employs tens of thousands of staff, making it one of the larger CROs active globally from the moment of its launch.
Fortrea's core offering centres on clinical development services, spanning Phase I through Phase IV trials across a broad range of therapeutic categories. The company provides site management, patient recruitment, data management, bioanalytical laboratory services, and regulatory affairs support, giving sponsors a largely integrated pathway from early-phase work through post-market studies.
Alongside its clinical operations, Fortrea runs an enabling services division that handles functional service provider arrangements, allowing biopharmaceutical clients to access specific capabilities without committing to a full-service model. This flexibility is particularly valued by mid-size and emerging biotechnology sponsors managing constrained timelines and budgets.
The company is publicly listed on the Nasdaq stock exchange under the ticker FTRE. Its client base spans large multinational pharmaceutical companies, specialist biotechnology firms, and medical device developers, with therapeutic depth in oncology, central nervous system disorders, infectious disease, cardiovascular medicine, and immunology.
Further information is available at fortrea.com.
